Comparison of pharmacodynamics and celiac effects of olmesartan medoxomil formulations by using olmesartan-induced celiac-rat-model

Basit Öğe Kaydı
dc.contributor.authorKömesli, Yelda
dc.contributor.authorErgur, Bekir Uğur
dc.contributor.authorKarasulu, Ercüment
dc.date.accessioned2022-04-06T08:04:30Z
dc.date.available2022-04-06T08:04:30Z
dc.date.issued2021en_US
dc.departmentFakülteler, Eczacılık Meslek Bilimleri Bölümü, Farmasötik Botanik Ana Bilim Dalıen_US
dc.description.abstractIntroduction: Olmesartan Medoxomil (OM) is an angiotensin receptor blocker and has the adverse effect of celiac like enteropathy which was accepted by the FDA in 2013. This disease is characterized by severe diarrhea, weight loss and enteropathy. Although there are many case reports associated with olmesartan-related enteropathy in humans, it has not been described in a long-term animal model study so far. Aim: We developed a self-microemulsifying drug delivery system (OM-SMEDDS) in our previous study to reduce this side effect of the drug and to enhance bioavailability. Methods: In this study, an artificial hypertension model was established with a dose of 185 μmol /kg L-NAME (N ω-nitro-L-arginine methyl ester) twice in a day intraperitoneally in Wistar albino rats. To determine and compare side effects, the OM-Suspension and OM-SMEDDS were administered at 1.3 mg/kg therapeutic dose during one-month period to the rats. Results: Tension of rats was recorded by measuring from their tails with non invasive blood pressure system. We observed celiac like enteropathy findings like villous atrophy and intraepithelial lymphocytosis and clinical changes like weight loss and severe diarrhea after the treatment with OM-Suspension during one-month experiment. It was also observed that the antihypertensive efficacy of the OM-SMEDDS formulation was higher than the suspension during the experiment, which did not cause enteropathy, diarrhea and weight loss by reducing intestinal exposure. Conclusion: Hereby, we evaluated the side effects of two different pharmaceutical forms by designing a sustainable and reproducible celiac rat model that can be induced with olmesartan medoxomil.en_US
dc.identifier.citationKomesli, Y., Ergur, B. U., & Karasulu, E. (2021). Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model. Current Drug Delivery, 18(10), 1515-1525.en_US
dc.identifier.endpage1525en_US
dc.identifier.issue10en_US
dc.identifier.scopus2-s2.0-85123650723
dc.identifier.scopusqualityQ2
dc.identifier.startpage1515en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/2315
dc.identifier.volume18en_US
dc.identifier.wosWOS:000721383900008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKömesli, Yelda
dc.language.isoen
dc.relation.ispartofCurrent Drug Delivery
dc.relation.isversionof10.2174/1567201818666210322144631en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypertensionen_US
dc.subjectSMEDDSen_US
dc.subjectDiarrheaen_US
dc.subjectEnteropathyen_US
dc.subjectOlmesartan Medoxomilen_US
dc.subjectOlmesartan-Induced Celiac Rat Modelen_US
dc.subjectPharmacodynamicsen_US
dc.titleComparison of pharmacodynamics and celiac effects of olmesartan medoxomil formulations by using olmesartan-induced celiac-rat-model
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Eczacılık Fakültesi Yayın Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize